Related Experiment Video
Updated: May 24, 2026
03:50
Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
Evaluating slow-transit constipation in patients using laxatives: a better approach or do we need improved patient
Gabrio Bassotti1, Vincenzo Villanacci, Sara Bologna
1Gastroenterology and Hepatology Section, Department of Clinical and Experimental Medicine, University of Perugia, Santa Maria della Misericordia Hospital, 1, 06156 San Sisto (Perugia), Italy. gabassot@tin.it
Expert Review of Gastroenterology & Hepatology
|March 2, 2012
Summary
Laxative use significantly improves daily bowel movements and stool consistency in slow-transit constipation patients. This highlights the importance of considering laxative effects when evaluating these individuals.
Area of Science:
- Gastroenterology
- Clinical Medicine
Background:
- Slow-transit constipation (STC) is a common, often treatment-resistant subtype of constipation.
- Current clinical evaluations typically occur during laxative withdrawal, limiting data on daily symptom impact.
- This study investigates the real-world effects of laxatives on daily symptoms in STC patients.
Discussion:
- Laxative use, even intermittently, normalized daily evacuation frequency for most STC patients.
- Patients reported significantly more frequent and looser stools on days they used laxatives.
- Enema use was also noted in a minority of patients.
Key Insights:
- Laxatives substantially influence daily symptoms and bowel movement frequency in STC.
- Intermittent laxative use can achieve near-normal bowel function.
- Clinical assessment of STC requires accounting for ongoing laxative therapy.
Outlook:
- Further research could explore optimal laxative regimens for STC.
- Understanding laxative impact is crucial for accurate STC diagnosis and management.
- This data aids clinicians in interpreting patient-reported outcomes during treatment.
Related Concept Videos
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:25Assessment of the Rectum and Anus
Evaluating the rectum and anus plays a crucial role in conducting a thorough physical examination of the gastrointestinal system. Although it may be uncomfortable and often embarrassing for the patient, it holds immense diagnostic value, particularly in detecting gastrointestinal diseases and abnormalities. This guide will explain how to perform this assessment using inspection and palpation methods.
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...